Reviva to Participate in the BIO International Convention
10-Q: Quarterly report
Reviva to Present New Preclinical Efficacy Data on Brilaroxazine in Idiopathic Pulmonary Fibrosis at 2024 ATS International Conference
Reviva Pharmaceuticals GAAP EPS of -$0.18
No Data